The effectiveness and safety of four Janus kinase inhibitors have been proven for the treatment of patients with rheumatoid arthritis. All drugs are associated with high rates of disease remission.
Scientists from Kobe Graduate School of Medicine (Japan) compared the effectiveness and safety of four Janus kinase inhibitors in clinical practice. The study results were published in the journal Rheumatology.
Data from 622 patients with rheumatoid arthritis treated with one of the drugs: tofacitinib, baricitinib, peficitinib, or upadacitinib were analyzed. Clinical disease activity, C-reactive protein levels, Modified Health Assessment Scale scores after treatment initiation, and rates of remission or low disease activity at six months were compared.
The frequency of temporary discontinuation and discontinuation of the drug six months after the start of treatment did not differ significantly among the four Janus kinase inhibitors. Moreover, after six months of therapy, there were no significant differences in mean clinical disease activity, remission rates, or rates of low disease activity.